Comparison of the King's and MiToS staging systems for ALS

Ton Fang, Ahmad Al Khleifat, Daniel R Stahl, Claudia Lazo La Torre, Caroline Murphy, Carolyn Young, Pamela J Shaw, P Nigel Leigh, Ammar Al-Chalabi, Uk-Mnd LicalS

Research output: Contribution to journalArticlepeer-review

65 Citations (Scopus)
173 Downloads (Pure)

Abstract

OBJECTIVE: To investigate and compare two ALS staging systems, King's clinical staging and Milano-Torino (MiToS) functional staging, using data from the LiCALS phase III clinical trial (EudraCT 2008-006891-31).

METHODS: Disease stage was derived retrospectively for each system from the ALS Functional Rating Scale-Revised subscores using standard methods. The two staging methods were then compared for timing of stages using box plots, correspondence using chi-square tests, agreement using a linearly weighted kappa coefficient and concordance using Spearman's rank correlation.

RESULTS: For both systems, progressively higher stages occurred at progressively later proportions of the disease course, but the distribution differed between the two methods. King's stage 3 corresponded to MiToS stage 1 most frequently, with earlier King's stages 1 and 2 largely corresponding to MiToS stage 0 or 1. The Spearman correlation was 0.54. There was fair agreement between the two systems with kappa coefficient of 0.21.

CONCLUSION: The distribution of timings shows that the two systems are complementary, with King's staging showing greatest resolution in early to mid-disease corresponding to clinical or disease burden, and MiToS staging having higher resolution for late disease, corresponding to functional involvement. We therefore propose using both staging systems when describing ALS.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalAmyotrophic lateral sclerosis & frontotemporal degeneration
Early online date5 Jan 2017
DOIs
Publication statusE-pub ahead of print - 5 Jan 2017

Fingerprint

Dive into the research topics of 'Comparison of the King's and MiToS staging systems for ALS'. Together they form a unique fingerprint.

Cite this